Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient

J Pediatr Hematol Oncol. 2024 Apr 1;46(3):e244-e247. doi: 10.1097/MPH.0000000000002841. Epub 2024 Mar 1.

Abstract

Resistant and refractory cytomegalovirus (CMV) viremia can limit the provision of chemotherapy due to myelosuppression and end-organ dysfunction. Few therapies are available for children with clinically significant CMV viremia. We successfully used maribavir for a 4-year-old patient with lymphoma to complete his chemotherapy course. Resistance to maribavir did result after many months of therapy.

Trial registration: ClinicalTrials.gov NCT05319353.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use
  • Benzimidazoles / therapeutic use
  • Child, Preschool
  • Cytomegalovirus Infections* / drug therapy
  • Dichlororibofuranosylbenzimidazole* / analogs & derivatives
  • Humans
  • Neoplasms* / drug therapy
  • Ribonucleosides* / therapeutic use
  • Viremia / drug therapy

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Dichlororibofuranosylbenzimidazole
  • maribavir
  • Ribonucleosides

Associated data

  • ClinicalTrials.gov/NCT05319353